VITAMIN D STATUS IN THALASSEMIA MAJOR: UN AGGIORNAMENTO

01 ottobre 2013

è stato pubblicato sulla rivista internazionale "MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES" l'articolo dal titolo "Vitamin D Status in Thalassemia Major: An Update", curato dal dott. Vincenzo De Sanctis.

Ashraf Soliman,¹ Vincenzo De Sanctis,² and Mohamed Yassin³
¹Departments of Pediatrics, Hamad Medical Center (HMC), Doha (Qatar)
²Pediatric, Adolescent Outpatient Clinic, Quisisana Hospital, 44121 Ferrara (Italy)
³Department of Hematology, Alamal Hospital, HMC, Doha, (Qatar)

Abstract

The survival of patients with thalassemia major has progressively improved with advances in therapy; however, osteoporosis and cardiac dysfunction remain frequent complications. Adequate circulating levels of vitamin D are essential for optimal skeletal health and reducing fracture risk. Vitamin D deficiency and insufficiency is reported to be high in thalassemic patients in many countries despite the presence of good sunshine and routine prescription of 400–1,000 IU vitamin D per day. The risk of vitamin D deficiency in thalassemia and its relation to bone disease; including osteoporosis, rickets, scoliosis, spinal deformities and fractures as well as to cardiac dysfunction is discussed in this mini-review. Monitoring and maintaining normal serum level of 25-OH vitamin D through oral intake of vitamin D and early correction of VDD by oral or parental use of vitamin D may significantly improve bone mineral accretion and ameliorate cardiac function.

PubMed Source: http://www.ncbi.nlm.nih.gov/pubmed/24106607

VITAMIN D STATUS IN THALASSEMIA MAJOR: UN AGGIORNAMENTO

Categorie

Ultimi post

Reparto di fisioterapia: benvenuto ...

La sincope neuromediata ad esordio ...

PLDD: Dr. Gian Paolo Tassi inizia ...

Quisisana a sostegno del Premio ...

Altri post della stessa categoria

La sincope neuromediata ad esordio nel giovane o nell’anziano: diverso significato prognostico?

Relationship between emotional bradycardia in animals and vasovagal syncope in humans. Physiol Behav

Neurally mediated syncope starting in old age does not appear to be unique to humans: new perspective

Emorragia gastrointestinale maggiore in corso di terapia anticoagulante nei pazienti con fibrillazione atriale: quando riprendere il trattamento?

Initial Clinical Evaluation

Il trattamento anticoagulante nei pazienti con fibrillazione atriale non valvolare e anemia cronica: ancora zone grigie

Quisisana: pubblicato sul Journal of Cardiovascular Medicine l'intervento del Dottor Alboni

I "Giovedì della salute" negli spazi del Poliambulatorio Quisisana di Ferrara

Il Dottor Stefano Romagnoli interviene su sarcopenia e il microbiota.

IL PROGETTO EQUALITY

TERAPIA DELLA SINCOPE SENOCAROTIDEA

IL SESTO MAGAZINE DEL PROGETTO EQUALITY

Prenota la tua visita online